Synthetic anti-infective biotech Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has confirmed it will publish an abstract and poster presentation at the 2023 Military Health System Research Symposium (MHSRS) in the US.
The abstract and poster publications will be accompanied by an in-person oral presentation by RCE executive chair Dr John Prendergast, presenting expanded details of in-vitro, in-vivo and human clinical trial data supporting the company’s lead synthetic anti-infective RECCE® 327.
The presentation is titled 'RECCE® 327: A Novel Synthetic Anti-infective for the Treatment of Antimicrobial-resistant Bacterial Sepsis Infections' and will be presented during the 'Antimicrobial Countermeasures for Wound Infections in Military Personnel' session.
DoD’s foremost scientific meeting
Recce Pharmaceuticals described the MHSRS as “the US Department of Defence’s foremost scientific meeting”.
It provides a venue to present military-specific novel scientific knowledge, drawing some 3,500 attendees of both the military and civilian persuasion with a focus on the unique medical needs of soldiers.
The symposium will be held in Kissimmee, Florida, from August 14-17, 2023.
A non-confidential version of the poster and abstract materials will be available on Recce’s website after the conference.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
- RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;
- RECCE® 435 as an orally administered therapy for bacterial infections; and,
- RECCE® 529 for viral infections.